Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer

Chen, Yia,b; Wang, Xiao-Lina,b; Wang, Jian-Huaa,b; Yan, Zhi-Pinga,b; Cheng, Jie-Mina,b; Gong, Gao-Quana,b; Liu, Ling-Xiaoa,b; Li, Guo-Pinga; Li, Chang-Yub

doi: 10.1097/CAD.0000000000000120

The aim of this study was to evaluate the therapeutic efficacy and the safety of transarterial infusion (TAI) with gemcitabine and oxaliplatin in patients with unresectable pancreatic cancer (PC). After celiac arteriogram and super-mesenteric arteriography, 1000 mg/m2 gemcitabine and 100 mg/m2 oxaliplatin were infused through 4- or 5-Fr catheters in arteries supplying blood to the tumor. In cases in which the blood-supplying artery could be selectively catheterized, the infusion was performed through a 3-Fr catheter placed in the tumor-supplying artery. Therapeutic courses were repeated every 4 weeks. The tumor response, the overall survival, and adverse effects were monitored. Thirty-two patients with unresectable PC were enrolled in this study, including 20 male and 12 female patients. A total of 105 cycles of TAI (mean=3.3 cycles/patient) were performed. Of 32 patients, partial remission was achieved in eight (25.0%), stable disease in 13 (40.6%), and progressive disease in 11 (34.4%). The overall response rate was 25.0%. The median survival time was 10.0 months (range=4–21 months). Grade III–IV toxicity, vomiting, occurred with a rate of 21.9%. Grade I–II neutropenia, thrombocytopenia, peripheral nerve toxicity, elevated serum transaminases levels, and serum total bilirubin were observed. TAI with gemcitabine and oxaliplatin is well tolerated and highly effective in patients with unresectable PC.

aDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University

bShanghai Institute of Medical Imaging, Shanghai, People’s Republic of China

Correspondence to Xiao-Lin Wang, MD, Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, People’s Republic of China Tel/fax: +86 21 64037258; e-mail:

Received September 9, 2013

Accepted March 23, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins